CLINICAL RESEARCH: HEART RHYTHM DISORDER
Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
A Meta-Analysis
Jeff S. Healey, MD*,*,
Adrian Baranchuk, MD*,
Eugene Crystal, MD ,
Carlos A. Morillo, MD*,
Michael Garfinkle, BA,
Salim Yusuf, MD, PhD* and
Stuart J. Connolly, MD*
* Population Health Research Institute, McMaster University, and Hamilton Health Sciences, Hamilton, Ontario, Canada
University of Toronto, Toronto, Ontario, Canada.
Manuscript received October 8, 2004;
revised manuscript received November 15, 2004,
accepted November 29, 2004.
* Reprint requests and correspondence: Dr. Jeff S. Healey, McMaster University-General Site, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada. (Email: healeyj{at}hhsc.ca).
OBJECTIVES: This study was designed to identify all randomized clinical trial data evaluating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for the prevention of atrial fibrillation (AF), to estimate the magnitude of this effect and to identify patient subgroups most likely to benefit.
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduce morbidity and mortality in patients with heart failure, vascular disease, and hypertension. Several reports suggest that they may also prevent the development of AF.
METHODS: A systematic review of the literature was performed to identify all reports of the effect of ACEIs or ARBs on the development of AF. Eligible studies had to be randomized, controlled, parallel-design human trials of an ACEI or ARB that collected data on the development of AF.
RESULTS: A total of 11 studies, which included 56,308 patients, were identified: 4 in heart failure, 3 in hypertension, 2 in patients following cardioversion for AF, and 2 in patients following myocardial infarction. Overall, ACEIs and ARBs reduced the relative risk of AF by 28% (95% confidence interval [CI] 15% to 40%, p = 0.0002). Reduction in AF was similar between the two classes of drugs (ACEI: 28%, p = 0.01; ARB: 29%, p = 0.00002) and was greatest in patients with heart failure (relative risk reduction [RRR] = 44%, p = 0.007). Overall, there was no significant reduction in AF in patients with hypertension (RRR = 12%, p = 0.4), although one trial found a significant 29% reduction in patients with left ventricular (LV) hypertrophy. In patients following cardioversion, there appears to be a large effect (48% RRR), but the confidence limits are wide (95% CI 21% to 65%).
CONCLUSIONS: Both ACEIs and ARBs appear to be effective in the prevention of AF. This benefit appears to be limited to patients with systolic left ventricular dysfunction or LV hypertrophy. The use of these drugs following cardioversion appears promising but requires further study.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | ACEI = angiotensin-converting enzyme inhibitor | | ARB = angiotensin-II receptor blocker | | CI = confidence interval | | HF = heart failure | | LVEF = left ventricular ejection fraction | | MI = myocardial infarction | | RAAS = renin-angiotensin-aldosterone system | | RRR = relative risk reduction |
|
This article has been cited by other articles:
|
|
|
|
 
E. Anter and D. J. Callans
Pharmacological and Electrical Conversion of Atrial Fibrillation to Sinus Rhythm Is Worth the Effort
Circulation,
October 6, 2009;
120(14):
1436 - 1443.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. K. Mason and J. P. DiMarco
New Pharmacological Agents for Arrhythmias
Circ Arrhythm Electrophysiol,
October 1, 2009;
2(5):
588 - 597.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hegbom, A. Tveit, I. Grundvold, H. Arnesen, and P. Smith
Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation
Europace,
October 1, 2009;
11(10):
1301 - 1307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-K. Wu, C.-D. Tseng, Y.-T. Huang, C.-S. Hsieh, W.-S. Tsai, J.-L. Lin, F.-T. Chiang, and C.-T. Tsai
Angiotensin II does not influence expression of sarcoplasmic reticulum Ca2 + ATPase in atrial myocytes
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2009;
10(3):
121 - 126.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. D. Smit, I. C. Van Gelder, H. Tomoda, M. Disertori, R. Latini, A. P. Maggioni, and the Gruppo Italiano per lo Studio della Sopravvive
Valsartan and Recurrent Atrial Fibrillation
N. Engl. J. Med.,
July 30, 2009;
361(5):
532 - 533.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al.
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Europace,
July 1, 2009;
11(7):
860 - 885.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. John Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al.
Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'
Eur. Heart J.,
June 17, 2009;
(2009)
ehp235v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schmitt, G. Duray, B. J. Gersh, and S. H. Hohnloser
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications
Eur. Heart J.,
May 1, 2009;
30(9):
1038 - 1045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Cappato
Atrial fibrillation complicating acute myocardial infarction: how should it be interpreted and how should it be treated and prevented?
Eur. Heart J.,
May 1, 2009;
30(9):
1035 - 1037.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. White, H. Ross, S. Levesque, L. Whittom, G. B Pelletier, N. Racine, S. Meloche, and L. Voisin
Effects of Angiotensin-Converting Enzyme Inhibitor Versus Valsartan on Cellular Signaling Events in Heart Transplant
Ann. Pharmacother.,
May 1, 2009;
43(5):
831 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C N Pellegrini, E Vittinghoff, F Lin, S B Hulley, and G M Marcus
Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial
Heart,
May 1, 2009;
95(9):
704 - 708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. T. McInnes
Telmisartan to Prevent Recurrent Stroke: The PRoFESS Study: Was the Baby Thrown Out With the Bathwater?
Stroke,
May 1, 2009;
40(5):
1938 - 1940.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Tian, R. Miyazaki, T. Ichiki, I. Imayama, K. Inanaga, H. Ohtsubo, K. Yano, K. Takeda, and K. Sunagawa
Inhibition of Tumor Necrosis Factor-{alpha}-Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor-{gamma} With Nuclear Factor {kappa}B and CCAAT/Enhancer-Binding Protein-{beta}
Hypertension,
May 1, 2009;
53(5):
798 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The GISSI-AF Investigators
Valsartan for Prevention of Recurrent Atrial Fibrillation
N. Engl. J. Med.,
April 16, 2009;
360(16):
1606 - 1617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Gillis
Angiotensin-Receptor Blockers for Prevention of Atrial Fibrillation -- A Matter of Timing or Target?
N. Engl. J. Med.,
April 16, 2009;
360(16):
1669 - 1671.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Benjamin, P.-S. Chen, D. E. Bild, A. M. Mascette, C. M. Albert, A. Alonso, H. Calkins, S. J. Connolly, A. B. Curtis, D. Darbar, et al.
Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop
Circulation,
February 3, 2009;
119(4):
606 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Smit and I. C. Van Gelder
Is inflammation a risk factor for recurrent atrial fibrillation?
Europace,
February 1, 2009;
11(2):
138 - 139.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Hansen, J. T. Hansen, T. Speerschneider, C. Lyngso, N. Erikstrup, E. S. Burstein, D. M. Weiner, T. Walther, N. Makita, T. Iiri, et al.
Lack of Evidence for AT1R/B2R Heterodimerization in COS-7, HEK293, and NIH3T3 Cells: HOW COMMON IS THE AT1R/B2R HETERODIMER?
J. Biol. Chem.,
January 16, 2009;
284(3):
1831 - 1839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Belluzzi, L. Sernesi, P. Preti, F. Salinaro, M. L. Fonte, and S. Perlini
Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.
J. Am. Coll. Cardiol.,
January 6, 2009;
53(1):
24 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bajpai, I. Savelieva, and A. J. Camm
Treatment of atrial fibrillation
Br. Med. Bull.,
December 5, 2008;
(2008)
ldn046v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Wachtell, R. B. Devereux, P. A. Lyle, P. M. Okin, and E. Gerdts
The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy
Therapeutic Advances in Cardiovascular Disease,
December 1, 2008;
2(6):
507 - 513.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y Blaauw and H J G M Crijns
Treatment of atrial fibrillation
Heart,
October 1, 2008;
94(10):
1342 - 1349.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bollmann, A. Tveit, D. Husser, M. Stridh, L. Sornmo, P. Smith, and S. B. Olsson
Fibrillatory rate response to candesartan in persistent atrial fibrillation
Europace,
October 1, 2008;
10(10):
1138 - 1144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs
Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Circulation,
September 16, 2008;
118(12):
1285 - 1293.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dorian and B. N. Singh
Upstream therapies to prevent atrial fibrillation
Eur. Heart J. Suppl.,
September 1, 2008;
10(suppl_H):
H11 - H31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Gillis, M. Morck, D. V. Exner, A. Soo, M. S. Rose, R. S. Sheldon, H. J. Duff, K. M. Kavanagh, L. B. Mitchell, and D. G. Wyse
Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation
Eur. Heart J.,
August 1, 2008;
29(15):
1873 - 1880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Cain and A. B. Curtis
Rhythm Control in Atrial Fibrillation -- One Setback after Another
N. Engl. J. Med.,
June 19, 2008;
358(25):
2725 - 2727.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Serra and M. Bendersky
Review: Atrial fibrillation and renin-angiotensin system
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
215 - 223.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Nattel, B. Burstein, and D. Dobrev
Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Circ Arrhythm Electrophysiol,
April 1, 2008;
1(1):
62 - 73.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Paraskevas
Applications of statins in cardiothoracic surgery: more than just lipid-lowering
Eur. J. Cardiothorac. Surg.,
March 1, 2008;
33(3):
377 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Burstein and S. Nattel
Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation
J. Am. Coll. Cardiol.,
February 26, 2008;
51(8):
802 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fauchier, B. Pierre, A. de Labriolle, C. Grimard, N. Zannad, and D. Babuty
Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
J. Am. Coll. Cardiol.,
February 26, 2008;
51(8):
828 - 835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goette, A. Bukowska, U. Lendeckel, M. Erxleben, M. Hammwohner, D. Strugala, J. Pfeiffenberger, F.-W. Rohl, C. Huth, M. P.A. Ebert, et al.
Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression
Circulation,
February 12, 2008;
117(6):
732 - 742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goette and U. Lendeckel
Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms
Europace,
February 1, 2008;
10(2):
238 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sakabe, A. Shiroshita-Takeshita, A. Maguy, C. Dumesnil, A. Nigam, T.-K. Leung, and S. Nattel
Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling
Circulation,
November 6, 2007;
116(19):
2101 - 2109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association
Europace,
November 1, 2007;
9(11):
1006 - 1023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Tardif and M. Talajic
Perindopril and prevention of atrial fibrillation
Eur. Heart J. Suppl.,
September 1, 2007;
9(suppl_E):
E25 - E29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Adam, G. Frost, F. Custodis, M. A. Sussman, H.-J. Schafers, M. Bohm, and U. Laufs
Role of Rac1 GTPase Activation in Atrial Fibrillation
J. Am. Coll. Cardiol.,
July 24, 2007;
50(4):
359 - 367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al.
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Eur. Heart J.,
June 11, 2007;
(2007)
ehm236v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. White, J. Kluger, K. Lertsburapa, O. Faheem, and C. I. Coleman
Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III
Eur. J. Cardiothorac. Surg.,
May 1, 2007;
31(5):
817 - 820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Mitchell, R. S. Vasan, M. J. Keyes, H. Parise, T. J. Wang, M. G. Larson, R. B. D'Agostino Sr, W. B. Kannel, D. Levy, and E. J. Benjamin
Pulse Pressure and Risk of New-Onset Atrial Fibrillation
JAMA,
February 21, 2007;
297(7):
709 - 715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Nasr, A. Bouzamondo, J.-S. Hulot, O. Dubourg, J.-Y. Le Heuzey, and P. Lechat
Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis
Eur. Heart J.,
February 8, 2007;
(2007)
ehl484v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Imayama, T. Ichiki, K. Inanaga, H. Ohtsubo, K. Fukuyama, H. Ono, Y. Hashiguchi, and K. Sunagawa
Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor {gamma}
Cardiovasc Res,
October 1, 2006;
72(1):
184 - 190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Okin, K. Wachtell, R. B. Devereux, K. E. Harris, S. Jern, S. E. Kjeldsen, S. Julius, L. H. Lindholm, M. S. Nieminen, J. M. Edelman, et al.
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
JAMA,
September 13, 2006;
296(10):
1242 - 1248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
651 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Strauss and A. S. Hall
Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox
Circulation,
August 22, 2006;
114(8):
838 - 854.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
854 - 906.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
e149 - e246.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
e257 - e354.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
700 - 752.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Eur. Heart J.,
August 2, 2006;
27(16):
1979 - 2030.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Y H Lip and A. Tello-Montoliu
Management of atrial fibrillation.
Heart,
August 1, 2006;
92(8):
1177 - 1182.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev,
July 1, 2006;
86(3):
747 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shimoni, D. Hunt, K. Chen, T. Emmett, and G. Kargacin
Differential autocrine modulation of atrial and ventricular potassium currents and of oxidative stress in diabetic rats
Am J Physiol Heart Circ Physiol,
May 1, 2006;
290(5):
H1879 - H1888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Ehrlich, S. H. Hohnloser, and S. Nattel
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
Eur. Heart J.,
March 1, 2006;
27(5):
512 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mascitelli and F. Pezzetta
Anti-Inflammatory Action of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
J. Am. Coll. Cardiol.,
February 21, 2006;
47(4):
889 - 889.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Healey, C. A. Morillo, and S. J. Connolly
Reply
J. Am. Coll. Cardiol.,
February 21, 2006;
47(4):
890 - 891.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Boos and G. Y.H. Lip
Prevention of Atrial Fibrillation by Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
J. Am. Coll. Cardiol.,
February 21, 2006;
47(4):
889 - 890.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V J Karthikeyan and G. Y H Lip
Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation
Evid. Based Med.,
February 1, 2006;
11(1):
15 - 15.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Boos, R. A. Anderson, and G. Y.H. Lip
Is atrial fibrillation an inflammatory disorder?
Eur. Heart J.,
January 2, 2006;
27(2):
136 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Kalus, C. I. Coleman, and C. M. White
The Impact of Suppressing the Renin-Angiotensin System on Atrial Fibrillation
J. Clin. Pharmacol.,
January 1, 2006;
46(1):
21 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nattel
Aldosterone antagonism and atrial fibrillation: time for clinical assessment?
Eur. Heart J.,
October 2, 2005;
26(20):
2079 - 2080.
[Full Text]
[PDF]
|
|
|
|
